FY2024 EPS Estimates for BioNTech Lowered by Leerink Partnrs

BioNTech SE (NASDAQ:BNTX) – Leerink Partnrs lowered their FY2024 EPS estimates for shares of BioNTech in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($3.79) per share for the year, down from their prior forecast of ($1.84). The consensus estimate for BioNTech’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for BioNTech’s Q4 2024 earnings at $0.42 EPS, Q1 2025 earnings at ($1.81) EPS, Q2 2025 earnings at ($2.30) EPS, Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $1.85 EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($2.04) EPS and FY2028 earnings at ($1.09) EPS.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The business’s revenue for the quarter was up 38.9% on a year-over-year basis.

A number of other analysts also recently issued reports on the stock. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, November 14th. TD Cowen cut their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and raised their price target for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $137.54.

BioNTech Stock Performance

Shares of BNTX opened at $101.87 on Monday. The company has a market cap of $24.42 billion, a price-to-earnings ratio of -48.51 and a beta of 0.26. The business’s fifty day simple moving average is $113.57 and its two-hundred day simple moving average is $97.36. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Covestor Ltd boosted its position in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after acquiring an additional 133 shares in the last quarter. GAMMA Investing LLC boosted its position in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. Planning Capital Management Corp raised its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.